Report : Asia Pacific Lymphedema Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Condition Type (Primary Lymphedema and Secondary Lymphedema), Treatment Type (Laser Therapy, Compression Devices and Bandaging, Drug Therapy, Physiological Procedures {Lymphovenous Anastomosis (LVA) and Vascularized Lymph Node Transfer (VLNT)}, Debulking Procedures {Surgical Debulking, Liposuction, and Others}, and Others), and End User (Hospitals, Clinics, Clinical Research Organizations, and Others)
Compression Devices and Bandaging Segment to Dominate APAC Lymphedema Treatment Market during 2021–2028
According to a new market research study on “APAC Lymphedema Treatment Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Condition Type, Treatment Type and End-User” is expected to reach US$ 1,546.52 million by 2028 from US$ 975.11 million in 2021. The market is estimated to grow at a CAGR of 6.8% from 2021 to 2028. The report provides trends prevailing in the APAC lymphedema treatment market along with the drivers and restraints pertaining to the market growth. Rising treatment options is the major factor driving the growth of the APAC lymphedema treatment market. However, issues associated with the lack of awareness and skilled professionals hinder the growth of APAC lymphedema treatment market.
The APAC lymphedema treatment market is segmented into condition type, treatment type, end-user and country. Based on type, the APAC lymphedema treatment market is segmented into primary lymphedema and secondary lymphedema. The secondary lymphedema segment dominated the market in 2020 and primary lymphedema is expected to be the fastest growing during the forecast period. Based on treatment type, the APAC lymphedema treatment market is segmented into laser therapy, compression devices and bandaging, drug therapy, physiological procedures, debulking procedures, and others. The compression devices and bandaging segment dominated the market in 2020 and debulking procedures segment is expected to be the fastest growing during the forecast period. Further physiological procedures segment is bifurcated into lymphovenous anastomosis (LVA) and vascularised lymph node transfer (VLNT).Based on end-user, the APAC lymphedema treatment market is segmented into hospitals, clinics, clinical research organizations, and others. The hospitals segment dominated the market in 2020 and clinics is expected to be the fastest growing during the forecast period. Based on country, APAC lymphedema treatment market is classified into China, Japan, India, Australia, South Korea, and Rest of APAC.
The 2019 novel coronavirus (2019-nCoV), officially named COVID-19 by the WHO, has spread to more than 180 countries, including China prompting the WHO to declare the disease a global pandemic. The supply chain disturbances and the tremendous demand for efficient treatments for the therapy of COVID-19 have put the healthcare research industry in a crucial situation in the Asia Pacific region. Prohibitive measures have been taken to control the spread of this pandemic. COVID-19 pandemic has broadly affected those economies in the Asia Pacific region. Countries such as India, China, Japan, South Korea were adversely affected by the pandemic. The socioeconomics was severely affected, rising in negative inflation, GDPs, and a regional unemployment surge. The outbreak has severely affected the medical tourism industry in Asia pacific and imposed supply chain disruptions; moreover, low-income countries face additional challenges due to the shortage of healthcare infrastructure, restrictions imposed by hospitals to the suppliers, decreasing in demand for cardiovascular surgical instruments, and others. There are various research studies on the reduction of surgeries in the Asia Pacific countries. Restrictive measures have been put forth in South Korea, Malaysia, Singapore, the Philippines, and India to prevent disease transmission. These restrictive measures impacted the supply chain and the availability of medical devices in these countries. It has affected disposable incomes and has also resulted in unemployment. Furthermore, business strategies such as acquisitions, mergers, and partnerships are adversely affected by the imposition of complete lockdown. However, increasing vaccination across the region and availability of government reimbursement policies for various diseases is expected to normalize the situation in the Asia Pacific region and will gradually increase the demand for lymphedema treatment.
3M Company, BSN medical GmbH, Huntleigh Healthcare Limited, Lohmann & Rauscher GmbH & Co. KG, Mego Afek ltd, Sigvaris Group, and Smith & Nephew are among the leading companies in the APAC lymphedema treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, Mego Afek ltd. has announced preliminary data for Lympha Press PCD-51 to be used in chronic venous stasis ulcers.
APAC Lymphedema Treatment Market, By Country, 2020 and 2028 (%)
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com